WUXI BIOLOGICS UNSP.ADR/2

Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI , April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor.» Mehr auf prnewswire.com

-          The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors-          Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20%-          As the company's largest operational single-use bioreactor to date, the system triples total site capacity to 23,000L, enabling flexible scale-up solutions HANGZHOU, China , April 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs) in the second drug substance line of its MFG20 facility at the Hangzhou site. The accomplishment not only marks a significant breakthrough as Asia's first 5,000L drug substance scale-up line utilizing SUBs, but also demonstrates the company's industry-leading capabilities in single-use technology (SUT) application for large-scale production, reaffirming its position at the forefront of advanced manufacturing solutions.» Mehr auf prnewswire.com

SHANGHAI , April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This also marks the seventh time that the company has been recognized by the organizer.» Mehr auf prnewswire.com